Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPL500036 in acute exacerbation of schizophrenia
2020-002316-51Phase 2Completed
- Sponsor
- Celon Pharma S.A.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing CPL500036 with Placebo (2 arms). Primary endpoint: Change from baseline in PANSS positive subscale at Week 4. Started Jun 2020; status: completed.
02
Drugs
cpl500036
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2020-002316-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002316-51.